Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a brain drug curb meth addiction?

NCT ID NCT03341078

Disease control Sponsor: VA Office of Research and Development Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether ibudilast, a drug that reduces brain inflammation, can help people addicted to methamphetamine. 176 participants took either ibudilast or a placebo for 6 weeks. Researchers used brain scans and thinking tests to see if the drug improved brain function and connectivity.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
ibudilast
What this could lead to
If successful, this could point toward a new medication to help people stop using methamphetamine.
What could go wrong
This is a small, early-phase trial focused on brain changes, not on stopping drug use directly. The drug may not work in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

176 people

The number who actually took part.

Started

May 2019

Finished

Oct 2025

Lead sponsor

A government agency

The lead sponsor is a US federal agency other than the NIH.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * abstinent from all drugs except marijuana and methamphetamine and have a negative urine drug screen on test days * Meet diagnosis for recent Methamphetamine-Use Disorder (DSM-V) or does not meet any substance-use disorders Exclusion Criteria: * Known sensitivity to ibudilast * Left handed * MRI contraindications * Clinically significant neurological, endocrine, renal, hepatic, or systemic diseases that would compromise safe participation or confound outcomes * Any psychiatric diagnoses or primary psychotic or mood disorders (past depression diagnoses allowed) * Any drug use disorder diagnosis besides methamphetamine or tobacco * Any recreational or prescriptive use of psychotropic medications * Claustrophobia * Women who are pregnant or breast-feeding * Neurodegenerative diseases that present with neuroinflammation * More than 4 weeks abstinent from methamphetamine * rs6971 genotype that confers low translocator protein (TSPO) binding affinity to prevent unnecessary radiation exposure * Liver disease requiring medication or medical treatment and/or aspartate or alanine aminotransferase levels greater than 3 times the upper limit * Participation in any drug study in the last 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Methamphetamine-dependence are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

methamphetamine dependence Neuroinflammatory Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Methamphetamine-dependence

Contacts and locations

Locations

  • VA Portland Health Care System, Portland, OR

    Portland, Oregon, 97207-2964, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.